Distinct patterns of inactivation of p15(INK4B) and p16(INK4A) characterize the major types of hematological malignancies

Cancer Research

Volumn 57, Issue 5, 1997, Pages 837-841

  Herman, James G ^a,b   Civin, Curt I ^a   Issa, Jean Pierre J ^a   Collector, Michael I ^a   Sharkis, Saul J ^a   Baylin, Stephen B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CHILDHOOD CANCER; CONTROLLED STUDY; DNA METHYLATION; GENE DELETION; GENE REPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; CARRIER PROTEINS; CELL CYCLE PROTEINS; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; LYMPHOMA; PROGNOSIS; SEQUENCE DELETION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0031025368     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Chen, Y. C., Chen, P. J., Yeh, S. H., Tien, H. F., Wang, C. H., Tang, J. L., and Hong, R. L. Deletion of the human retinoblastoma gene in primary leukemias. Blood, 76: 2060-2064, 1990.
2. Serrano, M., Hannon, G. J., and Beach. D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.). 366: 704-707, 1993.
3. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types, Science (Washington, DC). 264: 436-440, 1994.
4. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.). 368: 753-756, 1994.
5. Hannon, G. J., and Beach, D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
6. Ohnishi, H., Kawamura, M., Ida, K., Sheng, X. M., Hanada, R., Nobori, T., Yamamori, S., and Hayashi, Y. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood, 86: 1269-1275, 1995.
7. Hussussiun, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8: 15-21, 1994.
8. Stone, S., Dayananth, P., Jiang, P., Weaver-Feldhaus, J. M., Tavtigian, S. V., Cannon-Albright, L., and Kamb, A. Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene, 11: 987-991, 1995.
9. Guidal-Giroux, C., Gerard, B., Cave, H., Duval, M., Rohrlich, P., Elion, J., Vilmer, E., and Grandchamp, B. Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias. Br. J. Haematol., 92: 410-419, 1996.
10. Ogawa, S., Hangaishi, A., Miyawaki, S., Hirosawa, S., Miura, Y., Takeyama, K., Kamad,. N., Ohtake, S., Uike, N., Shimazaki, C., Toyama, K., Hirano, M., Mizoguchi, H., Kobayashi, Y., Furusawa, S., Saito, M., Emi, N., Yazaki, Y., Ueda, R., and Hirai, H. Loss of the cyclin-dependent kinase 4-inhihitor (p16\ MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood, 86: 1548-1556, 1995.
11. Quesnel, B., Preudhomme, C., Philippe, N., Vanrumbeke, M., Dervite, I., Lai, J. L., Bauters, F., Wattel, E., and Fenaux, P. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood, 85: 657-663, 1995.
12. Ogawa, S., Hirano, N., Sato, N., Takahashi, T., Hangaishi, A., Tanaka, K., Kurokawa, M., Tanaka, T., Mitani, K., Yazaki, Y., and Hirai, H. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood, 84: 2431-2435, 1994.
13. Fizzotti, M., Cimino, G., Pisegna, S., Alimena, G., Quartarone, C., Mandelli, F., Pelicci, P. G., and Lo Coco, F. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood, 85: 2685-2690, 1995.
14. Nakao, M., Yokota, S., Kaneko, H., Seriu, T., Koizumi, S., Takaue, Y., Fujimoto, T. Misawa, S. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia - mutations of CDKN2 are observed preferentially in T lineage. Leukemia (Baltimore), 10: 249-254, 1996.
15. Koduru, P. R., Zariwala, M., Soni, M., Gong, J. Z., Xiong, Y., and Broome, J. D. Deletion of cyclin-dependent kinase 4 inhibitor genes p15 and p16 in non-Hodgkin's lymphoma. Blood, 86: 2900-2905, 1995.
16. Otsuki, T., Clark, H. M., Wellmann, A., Jaffe, E. S., and Raffeld, M. Involvement of CDKN2 (p16INK4A/MTSl) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res., 55: 1436-1440, 1995.
17. Okuda, T., Shurtleff, S. A., Valentine, M. B., Raimondi, S. C., Head, D. R., Behm, F., Curcio-Brint, A. M., Liu, Q., Pui, C. H., Sherr, C. J., Beach, D., Look, A. T., and Downing, J. R. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood, 85: 2321-2330, 1995.
18. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P. J., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/P16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
19. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CPG island methylation is associated with transcriptional silencing of the tumour suppressor P16/CDKN2/MTS1 in human cancers, Nat. Med., 1: 686-692, 1995.
20. Herman, J. G., Jen, J., Merlo, A., und Baylin, S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15(INK4B). Cancer Res., 56: 722-727, 1996.
21. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M., and Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing, Cancer Res., 55: 4531-4535, 1995.
22. Otterson, G. A., Khleif, S. N., Chen, W., Coxon, A. B., and Kaye, F. J. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene, 11: 1211-1216, 1995.
23. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
24. Bedi, A., Zehnbauer, B. A., Collector, M. I., Barber, J. P., Zicha, M. S., Sharkis, S. J., and Jones, R. J. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood, 81: 2898-2902, 1993.
25. Krause, D. S., Fackler, M. J., Civin, C. I., and May, W. S. CD34. Structure, biology and clinical utility. Blood, 87: 1-13, 1996.
26. Jamal, R., Thomas, N. S. B., Gale, R. E., Linen, D. C. P16, and acute myeloid leukemia: variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level. Leukemia (Baltimore), 10: 629-636, 1996.
27. Hooper, W. C. The role of transforming growth factor-β in hematopoiesis: a review. Leukemia Res., 15: 179-184, 1991.
28. Uchida, T., Watanabe, T., Kinoshita, T., Murate, T., Saito, H., and Hotta. T. Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. Blood, 86: 2724-2731, 1995.
29. Serrano, M., Lee, H. W., Chin, L., Cordoncardo, C., Beach, D., and Depinho, R. A. Role of the INK4A locus in tumor suppression and cell mortality. Cell, 85: 27-37, 1996.
30. Sill, H., Goldman, J. M., and Cross, N. C. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood, 85: 2013-2016, 1995.